OptimizeRx (NASDAQ:OPRX) Issues Quarterly Earnings Results

OptimizeRx (NASDAQ:OPRX) announced its quarterly earnings data on Wednesday. The company reported $0.14 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.11), Zacks reports. OptimizeRx had a negative net margin of 27.41% and a negative return on equity of 4.92%. OptimizeRx updated its FY 2025 guidance to EPS.

OptimizeRx Stock Up 59.9 %

OPRX stock opened at $6.62 on Wednesday. The firm has a market cap of $121.97 million, a PE ratio of -4.70 and a beta of 1.31. The firm’s fifty day moving average is $5.41 and its 200 day moving average is $5.92. The company has a debt-to-equity ratio of 0.29, a quick ratio of 3.23 and a current ratio of 3.23. OptimizeRx has a one year low of $3.78 and a one year high of $14.80.

Insider Buying and Selling

In other OptimizeRx news, CEO William J. Febbo purchased 20,000 shares of the firm’s stock in a transaction dated Thursday, December 12th. The shares were purchased at an average cost of $5.01 per share, with a total value of $100,200.00. Following the completion of the purchase, the chief executive officer now owns 601,253 shares in the company, valued at approximately $3,012,277.53. This represents a 3.44 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. 6.10% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

OPRX has been the topic of several recent research reports. JMP Securities restated a “market outperform” rating and set a $8.00 target price on shares of OptimizeRx in a research report on Thursday, February 6th. Lake Street Capital reaffirmed a “buy” rating and set a $11.00 price target on shares of OptimizeRx in a research note on Tuesday, December 24th. B. Riley reduced their price objective on shares of OptimizeRx from $17.00 to $13.00 and set a “buy” rating for the company in a research note on Tuesday, December 24th. Stephens started coverage on shares of OptimizeRx in a research report on Friday, December 20th. They set an “equal weight” rating and a $5.50 price target for the company. Finally, William Blair reiterated an “outperform” rating on shares of OptimizeRx in a research note on Thursday, November 14th. Three investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat.com, OptimizeRx has an average rating of “Moderate Buy” and an average price target of $9.06.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.